The ELEVIDYS impact

Lotties

1 - src: /sites/default/files/2026-07/Interior-Crescent-10-Green_0.json / styles: top: 315px; left: -797px; height: 1650px; position: absolute; / loop: On

2 - src: /sites/default/files/2026-07/Interior-Crescent-13-Green.json / styles: top: -680px; right: -253px; width: 521px;; height: 1307px; position: absolute; / loop: On

ELEVIDYS slowed disease progression^*

based on multiple measures of everyday movement

ELEVIDYS helped people

score higher on tests of everyday movements

ELEVIDYS helped people

get up from the floor faster

ELEVIDYS helped people

walk/run faster

* Results were assessed at 1 year vs placebo and at 3 years vs external control. Additional assessments at 3 years are considered exploratory. Talk to your doctor to learn more.

The NSAA looks at how well participants can perform 17 different everyday movements

Each movement is scored on a scale (0=the person cannot complete the movement at all; 1=they require help; 2=they can accomplish it independently). Scores are checked at different points to track changes over time. If a score increases by 1 or 2 points, it means a person maintained or improved their ability to perform that movement.

With ELEVIDYS, participants got up from the floor faster

as measured by the average change in time to rise from the floor

graphic-test-time-to-rise-3-year-desktop

Getting up from the floor faster after treatment suggests a delay in disease progression

^† Additional assessments are considered exploratory. Talk to your doctor to learn more.

All participants had similar characteristics (eg, age, physical ability) at the start of the study and were on stable doses of steroids.

Walking/running faster after treatment suggests a delay in disease progression

Next up: Explore micro-dystrophin results

Now that you’ve seen how ELEVIDYS can slow disease progression, learn more about how it directly addresses the absence of dystrophin in Duchenne.

Proven to produce ELEVIDYS micro-dystrophin

The average increase in ELEVIDYS micro-dystrophin was consistent

People with Duchenne who are untreated typically have little to no dystrophin.

Next up: Explore muscle loss data

Now that you’ve seen how ELEVIDYS directly addresses the absence of dystrophin in Duchenne, learn more about its impact on muscle loss.

The ELEVIDYS impact